Switching from clozapine to zotepine in patients with schizophrenia: A 12-week prospective, randomized, rater blind, and parallel study

Journal of Clinical Psychopharmacology

Volumn 33, Issue 2, 2013, Pages 211-214

  Lin, Chao Cheng ^a   Chiu, Hsien Jane ^b   Chen, Jen Yeu ^c   Liou, Ying Jay ^d   Wang, Ying Chieh ^c,e   Chen, Tzu Ting ^c   Bai, Ya Mei ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Jianan Mental Hospital   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TZU CHI UNIVERSITY   (Taiwan)

Author keywords

antipsychotics; clozapine; schizophrenia; switch; zotepine

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; PROLACTIN; PROPRANOLOL; ZOTEPINE;

ADULT; AGED; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; KLINISKE UNDERSOGELSER RATING SCALE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; TREATMENT DURATION;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DIBENZOTHIEPINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874942307     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31828700c7     Document Type: Article

References (22)

1. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38(1):167-177.
2. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163.
3. Littrell KH, Johnson CG, Hilligoss NM, et al. Switching clozapine responders to olanzapine. J Clin Psychiatry. 2000;61(12):912-915. (Pubitemid 32058005)
4. Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry. 1998;59(11):585-588. (Pubitemid 28555419)
5. Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry. 2000;61(11):833-840.
6. Peuskens J. Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol. 2000;15(suppl 4):S15YS19.
7. McEvoy JP, Freudenreich O. Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking. Evid Based Ment Health. 2011;14(2):53.
8. Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(11):CD006633. doi: 10.1002/14651858. CD006633.pub2.
9. de Leon J, Greenlee B, Barber J, et al. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil. 2009;30(4):613-669.
10. Still DJ, Dorson PG, Crismon ML, et al. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv. 1996;47(12):1382-1384. (Pubitemid 26406077)
11. Jong-Yih L. Successful switch from clozapine to aripiprazole: a case report. J Clin Psychopharmacol. 2009;29(1):93-95.
12. Subramanian S, Rummel-Kluge C, Hunger H, et al. Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(10):CD006628. doi: 10.1002/14651858. CD006628.pub3.
13. Fleischhacker WW, Barnas C, Stuppack CH, et al. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull. 1989;25(1):97-100. (Pubitemid 19179169)
14. Barnas C, Stuppack CH, Miller C, et al. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. Int Clin Psychopharmacol. 1992;7(1):23-27.
15. Fleischhacker WW, Barnas C, Stuppack C, et al. Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry. 1987;20(1 Spec No):58-60. (Pubitemid 17042536)
16. Petit M, Raniwalla J, Tweed J, et al. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull. 1996;32(1):81-87.
17. Cooper SJ, Butler A, Tweed J, et al. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology (Berl). 2000;150(3):237-243. (Pubitemid 30447842)
18. Hashimoto K, Sudo T, Hirano M, et al. Efficacy and safety of zotepine for patients with treatment-resistant schizophrenia. Schizophr Res. 2006;87(1-3):332-333. (Pubitemid 44428119)
19. Green B. Zotepine: a clinical review. Expert Opin Drug Metab Toxicol. 2009;5(2):181-186.
20. Needham PL, Atkinson J, Skill MJ, et al. Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol Bull. 1996;32(1):123-128. (Pubitemid 26176212)
21. Yoshida H, Kaiya H, Kondo T, et al. Effects of zotepine, a psychotropic agent, on the serum uric acid level of inpatients at a psychiatric hospital [article in Japanese]. Yakubutsu Seishin Kodo. 1982;2(2):69-76. (Pubitemid 13150415)
22. Chen TT, Chen JY, Bai YM, et al. The effects of zotepine in treating psychotic patients with hyperuricaemia: a case series. Int J Neuropsychopharmacol. 2006;9(2):259-261.